CD40/CD154 interactions at the interface of tolerance and immunity - PubMed (original) (raw)
Review
CD40/CD154 interactions at the interface of tolerance and immunity
Sergio A Quezada et al. Annu Rev Immunol. 2004.
Abstract
Development of the acquired immune response is dependent on the signaling of CD40 by its ligand, CD154. These molecules govern both the magnitude and quality of humoral- and cell-mediated immunity. A litany of studies have conclusively documented that blockade of this ligand-receptor pair can prevent, and also intervene in, the progression of antibody- and cell-mediated autoimmune diseases, and can instill long-lived allogeneic and xenogeneic graft tolerance. Many effector mechanisms of inflammation are abolished as a result of CD154 blockade, but we are now beginning to understand that CD154 blockade may, in some instances, engender long-lived, antigen-specific tolerance. In the context of transplantation tolerance, we present a hypothesis that alpha CD154 blockade is most effective at inducing long-lived allospecific tolerance if anergy and regulation can be elicited prior to the onslaught of inflammation that is induced by grafting (preemptive tolerance). This facet of alpha CD154-induced tolerance appears to co-opt the normal processes of peripheral tolerance induced by immature DCs and can be exploited to induce long-lived antigen-specific tolerance. The underlying science and the prospects for inducing long-lived antigen-specific tolerance in a model of allograft tolerance through CD154 blockade are presented and discussed.
Similar articles
- CD40 and tolerance induction.
Karimi MH, Pourfathollah AA. Karimi MH, et al. Iran J Allergy Asthma Immunol. 2012 Mar;11(1):1-13. Iran J Allergy Asthma Immunol. 2012. PMID: 22427471 Review. - Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival.
Gao W, Demirci G, Strom TB, Li XC. Gao W, et al. Transplantation. 2003 Sep 27;76(6):994-9. doi: 10.1097/01.TP.0000085010.39567.FB. Transplantation. 2003. PMID: 14508368 - Determinations of B cell fate in immunity and autoimmunity.
Noelle RJ, Erickson LD. Noelle RJ, et al. Curr Dir Autoimmun. 2005;8:1-24. doi: 10.1159/000082084. Curr Dir Autoimmun. 2005. PMID: 15564715 Review. - Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.
Sun W, Wang Q, Zhang L, Liu Y, Zhang M, Wang C, Wang J, Cao X. Sun W, et al. Transplantation. 2003 Nov 15;76(9):1351-9. doi: 10.1097/01.TP.0000083557.25887.EE. Transplantation. 2003. PMID: 14627915 - Disruption of CD154:CD40 blocks generation of allograft immunity without affecting APC activation.
Shepherd DM, Kerkvliet NI. Shepherd DM, et al. J Immunol. 1999 Sep 1;163(5):2470-7. J Immunol. 1999. PMID: 10452982
Cited by
- Dysfunction of dendritic cells in tumor microenvironment and immunotherapy.
Chen J, Duan Y, Che J, Zhu J. Chen J, et al. Cancer Commun (Lond). 2024 Sep;44(9):1047-1070. doi: 10.1002/cac2.12596. Epub 2024 Jul 25. Cancer Commun (Lond). 2024. PMID: 39051512 Free PMC article. Review. - Historical overview of immunological tolerance.
Schwartz RH. Schwartz RH. Cold Spring Harb Perspect Biol. 2012 Apr 1;4(4):a006908. doi: 10.1101/cshperspect.a006908. Cold Spring Harb Perspect Biol. 2012. PMID: 22395097 Free PMC article. Review. - Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy.
Hassan HA, Smyth L, Wang JT, Costa PM, Ratnasothy K, Diebold SS, Lombardi G, Al-Jamal KT. Hassan HA, et al. Biomaterials. 2016 Oct;104:310-22. doi: 10.1016/j.biomaterials.2016.07.005. Epub 2016 Jul 14. Biomaterials. 2016. PMID: 27475727 Free PMC article. - Immunity to Cryptosporidium: Lessons from Acquired and Primary Immunodeficiencies.
Cohn IS, Henrickson SE, Striepen B, Hunter CA. Cohn IS, et al. J Immunol. 2022 Dec 15;209(12):2261-2268. doi: 10.4049/jimmunol.2200512. J Immunol. 2022. PMID: 36469846 Free PMC article. - T-cell agonists in cancer immunotherapy.
Choi Y, Shi Y, Haymaker CL, Naing A, Ciliberto G, Hajjar J. Choi Y, et al. J Immunother Cancer. 2020 Oct;8(2):e000966. doi: 10.1136/jitc-2020-000966. J Immunother Cancer. 2020. PMID: 33020242 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials